{"id":64113,"date":"2026-04-28T11:11:03","date_gmt":"2026-04-28T03:11:03","guid":{"rendered":"https:\/\/flcube.com\/?p=64113"},"modified":"2026-04-28T11:11:04","modified_gmt":"2026-04-28T03:11:04","slug":"bebetter-medicine-secures-fda-clearance-for-bebt-701-clinical-study-first-in-class-dual-target-therapy-for-hypertension-and-high-ldl-c","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64113","title":{"rendered":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C"},"content":{"rendered":"\n<p><strong>Guangzhou BeBetter Medicine Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688759:SHA\">SHA: 688759<\/a>) announced it has received approval from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> to initiate a clinical study of <strong>BEBT-701<\/strong>, its first investigational new drug to enter human trials, for the treatment of <strong>mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical study authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BEBT-701 (first-in-human investigational drug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Mild-to-moderate hypertension with elevated LDL-C<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>First-in-human clinical trial<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Proprietary GalNAc-based Di-oligonucleotide Conjugation (GDOC)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: BEBT-701, single-molecule dual-target oligonucleotide therapeutic<\/li>\n\n\n\n<li><strong>Targets<\/strong>: Simultaneously silences <strong>angiotensinogen (AGT)<\/strong> and <strong>proprotein convertase subtilisin\/kexin type 9 (PCSK9)<\/strong> within hepatocytes<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First-in-class approach using single administration for dual-pathway synergy<\/li>\n\n\n\n<li><strong>Technology<\/strong>: Proprietary <strong>GDOC platform<\/strong> enables targeted delivery to hepatocytes via GalNAc conjugation<\/li>\n\n\n\n<li><strong>Therapeutic Strategy<\/strong>: Coordinated regulation of both blood pressure and lipid metabolism pathways<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-rationale-amp-patient-benefits\">Clinical Rationale &amp; Patient Benefits<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Benefit<\/th><th>Impact<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Dual-Pathway Efficacy<\/strong><\/td><td>Simultaneous improvement in blood pressure and LDL-C levels<\/td><td>Addresses two major cardiovascular risk factors with single therapy<\/td><\/tr><tr><td><strong>Long-Acting Effect<\/strong><\/td><td>Extended duration of action<\/td><td>Reduced dosing frequency compared to standard therapies<\/td><\/tr><tr><td><strong>Patient Compliance<\/strong><\/td><td>Improved adherence due to simplified regimen<\/td><td>Better long-term outcomes through consistent treatment<\/td><\/tr><tr><td><strong>High-Risk Population<\/strong><\/td><td>Comprehensive chronic disease management for cardiovascular high-risk patients<\/td><td>Targeted solution for complex comorbid conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-significance\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: Limited options for patients with comorbid hypertension and hypercholesterolemia<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Novel dual-target approach represents significant innovation in cardiovascular therapeutics<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Successful development would validate BeBetter&#8217;s proprietary GDOC technology platform for future pipeline candidates<\/li>\n\n\n\n<li><strong>Global Relevance<\/strong>: Cardiovascular disease remains leading cause of death worldwide, creating substantial market opportunity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<p>As BeBetter&#8217;s first clinical-stage asset, BEBT-701 represents a critical milestone for the company&#8217;s transition from preclinical research to clinical development. The dual-target mechanism could establish a new paradigm for managing cardiovascular risk factors, potentially reducing polypharmacy and improving patient outcomes in high-risk populations.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial potential for BEBT-701. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688759_20260428_O5FY.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688759_20260428_O5FY.\"><\/object><a id=\"wp-block-file--media-871a30d1-5385-49d9-8934-9bfd43b647ad\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688759_20260428_O5FY.pdf\">688759_20260428_O5FY<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688759_20260428_O5FY.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-871a30d1-5385-49d9-8934-9bfd43b647ad\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4200,62,69,4589],"class_list":["post-64113","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bebetter-medicine-technology","tag-clinical-trial-approval-initiation","tag-cvd","tag-sha-688759"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64113\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C\" \/>\n<meta property=\"og:description\" content=\"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64113\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T03:11:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T03:11:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C\",\"datePublished\":\"2026-04-28T03:11:03+00:00\",\"dateModified\":\"2026-04-28T03:11:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113\"},\"wordCount\":377,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeBetter Medicine Technology\",\"Clinical trial approval \\\/ initiation\",\"CVD\",\"SHA: 688759\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64113#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64113\",\"name\":\"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T03:11:03+00:00\",\"dateModified\":\"2026-04-28T03:11:04+00:00\",\"description\":\"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64113\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64113#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C - Insight, China&#039;s Pharmaceutical Industry","description":"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64113","og_locale":"en_US","og_type":"article","og_title":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C","og_description":"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).","og_url":"https:\/\/flcube.com\/?p=64113","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T03:11:03+00:00","article_modified_time":"2026-04-28T03:11:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64113#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64113"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C","datePublished":"2026-04-28T03:11:03+00:00","dateModified":"2026-04-28T03:11:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64113"},"wordCount":377,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeBetter Medicine Technology","Clinical trial approval \/ initiation","CVD","SHA: 688759"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64113#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64113","url":"https:\/\/flcube.com\/?p=64113","name":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T03:11:03+00:00","dateModified":"2026-04-28T03:11:04+00:00","description":"Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of BEBT-701, its first investigational new drug to enter human trials, for the treatment of mild-to-moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64113#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64113"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64113#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study \u2013 First-in-Class Dual-Target Therapy for Hypertension and High LDL-C"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64113"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64113\/revisions"}],"predecessor-version":[{"id":64115,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64113\/revisions\/64115"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}